Company Profile
Easywell Biomedicals develops, manufactures, and sells generic pharmaceutical ingredients and products in America, China, and Taiwan. The company develops TLX-001, an anti-cough medicine.
Its portfolio also includes TLX-005, an anti-urinary incontinence medicine, TLX-006 for the treatment of breast cancer in PMS women, TLX-007 and TLX-004, which are anti-depressants, TLX-008 for the prevention of pneumocystis pneumonia, TLX-012 for the treatment of epilepsy, TLX-017 for the treatment of chronic angina, and TLX-011 for the treatment of inflammatory lesions of rosacea.
It is also developing TLX-015, a medicine for the prevention and treatment of postpartum hemorrhage. Its portfolio also includes TLX-018, a hemorrhage treatment drug, TLX-030, a medication for adrenal insufficiency treatment, TLX-047, a systemic corticosteroid, HH-001, a sacubitril/valsartan sodium tablet, TLX-024, a liquid oral anticonvulsant, TLX-034, an endocrine drug, TWB-201, a Parkinson patch, TLX-501, a urinary medicine, and TLX-502, a pneumonia medicine
Health food and products; and over-the-counter drugs. Incorporated in 1998 and headquartered in Hsinchu City, Taiwan, Easywell Biomedicals was formerly known as Actherm Inc. before rebranding in July 2015.